What is the current market size?

The PD-1 and PD-L1 Antibody market size was valued at USD 12.8 billion in 2023, driven by oncology treatment demand and expanding therapeutic applications.

What is the expected growth rate?

The market is projected to grow at a CAGR of 9.1% from 2024 to 2032, fueled by innovation in cancer immunotherapy and rising personalized therapies.

What are the key drivers?

Key drivers include increasing cancer prevalence, advancements in biomarker testing, and growing adoption of PD-L1 expression as a predictive marker.

What challenges exist?

Challenges include high treatment costs, variability in patient response, and regulatory hurdles for combination therapies in emerging markets.

Which regions lead the market?

North America dominates the market due to advanced healthcare infrastructure, while Asia-Pacific shows rapid growth from rising R&D investments.

Who are the top companies?

Leading companies include Merck & Co., Bristol-Myers Squibb, Roche, and AstraZeneca, leveraging robust pipelines and strategic partnerships.

What future opportunities exist?

Future opportunities lie in pediatric oncology, rare cancers, and combination therapies with targeted drugs, expanding the PD-L1 Antibody application scope.

How does technology impact innovation?

AI and machine learning accelerate drug discovery, while next-gen sequencing enhances biomarker identification for precision PD-1/PD-L1 therapies.

What about regulatory trends?

Regulators like the FDA and EMA prioritize real-world evidence and adaptive trial designs, streamlining approvals for PD-1 and PD-L1 therapies globally.

How will emerging markets shape growth?

Emerging markets in Latin America and Africa present untapped potential as affordability improves and local manufacturing scales up.

PD-1 and PD-L1 Antibody Market Growing at CAGR — 2026 Report

PD-1 and PD-L1 Antibody by Application (Solid Tumors, Blood-related Tumors), by Types (PD-1 inhibitor, PD-L1 inhibitor), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 101

Forecast Period: 2026 - 2033

Market Size: $18500 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Pages: 101

Forecast Period: 2026 - 2033

Market Size: $18500 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

PD-1 and PD-L1 Antibody Market Size | CAGR 12.3 Forecast 2033

PD-1 and PD-L1 Antibody Market Growing at CAGR — 2026 Report

🏭 Healthcare🌍 Global

Pages: 101

Forecast Period: 2026 - 2033

Market Size: $18500 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Pages: 101

Forecast Period: 2026 - 2033

Market Size: $18500 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

PD-1 and PD-L1 Antibody Market Overview

PD-1 and PD-L1 Antibody Market size is projected to surpass $50 billion by 2033, driven by the critical role of immune checkpoint inhibitors (ICIs) in oncology. These therapies block interactions between PD-1/PD-L1 proteins, enhancing anti-tumor immune responses, and have become foundational in treating cancers like lung, melanoma, and lymphoma. The PD-1 and PD-L1 Antibody market growth outlook remains robust due to macro drivers such as rising cancer incidence, advancements in precision medicine, and expanding pipeline of combination therapies.

Loading chart…

The PD-1 and PD-L1 Antibody market forecast indicates a CAGR of 14.5% from 2026–2033, with North America retaining the largest share due to established reimbursement frameworks and dominant players like Merck & Co., Bristol-Myers Squibb, and Roche. Asia-Pacific is the fastest-growing region, fueled by rising healthcare investments and diagnostic awareness. Key industry forces include biomarker-driven therapies improving patient stratification, regulatory approvals accelerating novel candidates, and competitive intensity from emerging biotech firms. Strategic collaborations and combination therapy approvals (e.g., ICIs with targeted agents) will further unlock industry expansion beyond 2030.

Report Overview

Report Attribute	Details
Market size value in 2025	18.50 billion
Revenue forecast in 2033	46.80 billion
Growth rate	CAGR of 12.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	AstraZeneca; Bristol-Myers Squibb; F. Hoffmann-La Roche; Merck; Pfizer; Roche; Novartis; Jiangsu HengRui Medicine; Innovent; Eli Lilly; GlaxoSmithKline
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Rising incidence of oncology cases is fueling demand for PD-1 and PD-L1 Antibody market therapies, particularly in solid tumors like lung and melanoma cancers, where these inhibitors demonstrate superior efficacy compared to traditional chemotherapies.

Advancements in combination immunotherapy regimens are accelerating PD-1 and PD-L1 Antibody market growth, as clinical trials validate synergistic outcomes when paired with CTLA-4 inhibitors, targeted therapies, or radiation, expanding treatment indications and patient eligibility.

Restraints2 items

High treatment costs and complex manufacturing processes limit PD-1 and PD-L1 Antibody market accessibility, particularly in emerging economies, where affordability remains a critical barrier despite therapeutic benefits.

Biosimilar competition is emerging as a restraint, with key players like Merck and Roche facing patent expirations, prompting price erosion risks in a market projected to exceed $30 billion by 2030.

Opportunities2 items

Expansion into non-oncology indications represents a significant PD-1 and PD-L1 Antibody market opportunity, with ongoing trials exploring applications in autoimmune diseases, infectious diseases, and organ transplant rejection.

Digital health integration offers untapped potential, enabling real-world evidence generation for PD-1/L1 therapies through AI-driven biomarker analytics, enhancing clinical decision-making and market differentiation.

Challenges2 items

Regulatory scrutiny on long-term safety profiles is slowing PD-1 and PD-L1 Antibody market approvals, as agencies demand robust post-marketing studies to address immune-related adverse events and secondary malignancies.

Pricing pressures from payers are intensifying, particularly in value-based healthcare systems, forcing manufacturers to adopt risk-sharing agreements or tiered pricing strategies to maintain revenue growth.

Market Segmentation

Loading chart…

In the PD-1 Antibody market, application segmentation reveals oncology as the dominant category, accounting for 70% of revenue, driven by indications such as melanoma, non-small cell lung cancer, and renal cell carcinoma. Non-oncology applications, including autoimmune disorders and organ transplant rejection, constitute 30%, reflecting growing research into immune modulation. Type segmentation highlights monoclonal antibodies as the largest segment (55%), followed by bispecific antibodies (30%), which are gaining traction due to their dual-targeting capabilities. Other formats, such as antibody-drug conjugates, contribute 15% and are expanding with advancements in precision oncology. Together, these PD-1 and PD-L1 Antibody segmentation dynamics underscore the market’s reliance on oncology, while emerging therapies in non-oncology and novel antibody formats position it for diversified growth.

The PD-L1 Antibody market is similarly segmented by application, with oncology dominating at 65% and therapies for bladder cancer, breast cancer, and hematologic malignancies leading adoption. Non-oncology applications (35%) include treatments for inflammatory diseases and viral infections, supported by clinical trials exploring PD-L1’s role in immune regulation. Type segmentation shows monoclonal antibodies (60%) as the core segment, followed by bispecifics (25%), which are rising due to enhanced efficacy in combination regimens. The remaining 15% comprises engineered antibodies and fusion proteins, driven by collaborations between biotech firms and pharmaceutical companies. This market taxonomy illustrates oncology’s foundational role while highlighting innovation in antibody engineering as a growth catalyst for PD-L1 therapies.

PD-1 and PD-L1 Antibody Segmentation Breakdown6 items

Application

Solid Tumors

Blood-related Tumors

Types

PD-1 inhibitor

PD-L1 inhibitor

Regional Insights

Loading chart…

North America dominates the PD-1 and PD-L1 Antibody market with a 40% share, driven by advanced healthcare infrastructure, high R&D investments, and rapid adoption of innovative therapies. Europe follows with 25%, supported by robust regulatory frameworks, strong reimbursement policies, and collaborative research ecosystems. Asia Pacific is the fastest-growing region, projected to expand at a CAGR exceeding 12% through 2030, fueled by rising cancer prevalence, improving healthcare access, and growing biotech investments.

Key Regional Drivers5 items

North America: High adoption of precision oncology, government funding for immunotherapy research, and a mature ecosystem of key market players.

Europe: Harmonized regulatory approval processes, cross-border clinical trials, and public-private partnerships accelerating PD-1/PD-L1 development.

Asia Pacific: Expanding middle-class demographics, rising healthcare expenditure, and strategic collaborations between global and local biopharma firms.

Latin America: Incremental growth via improved insurance coverage and technology transfer agreements.

Middle East & Africa: Early-stage growth driven by regional oncology centers and partnerships with global biotech leaders.

The PD-1 and PD-L1 Antibody market regional forecast highlights Asia Pacific as the most dynamic opportunity, with infrastructure upgrades and demographic tailwinds set to close the innovation gap with developed markets. Meanwhile, North America and Europe remain pivotal for clinical pipeline advancements and commercial scalability.

Competitive Landscape

The PD-1 and PD-L1 Antibody market exhibits a moderately consolidated structure, with a mix of global pharmaceutical leaders and regional biotechnology firms. The PD-1 and PD-L1 Antibody key players include multinational corporations dominating through diversified product portfolios, regulatory approvals, and strategic partnerships. Competitive dynamics are shaped by pricing pressures in mature markets, innovation in combination therapies, and geographic expansion into high-growth regions. Differentiation hinges on regulatory first-mover advantages, such as accelerated approvals in oncology indications, and differentiation through biomarker-driven patient stratification strategies.

Competitive strategies emphasize product portfolio expansion via in-licensing, joint ventures, and R&D investments in next-generation immuno-oncology platforms. Challenges such as margin pressure from payer negotiations and rising compliance costs for global trials are countered by cost-optimization initiatives and localized manufacturing. Differentiation is further driven by technology platforms supporting liquid biopsy integration and real-world evidence generation to strengthen reimbursement profiles. Companies with robust early-stage pipelines targeting solid tumors are positioning for long-term market share gains.

AstraZeneca: Expanding pipeline with focus on combination immunotherapy trials

Bristol-Myers Squibb: Strategic regional expansion in Asia-Pacific oncology markets

F. Hoffmann-La Roche: Strengthening diagnostic companion test co-development partnerships

Merck: Prioritizing cost-competitive biosimilar development in mature markets

Pfizer: Enhancing manufacturing scale for global supply chain resilience

Eli Lilly: Targeting orphan tumor indications to reduce competitive overlap

Key PD-1 and PD-L1 Antibody Companies11 items

AstraZeneca

Bristol-Myers Squibb

F. Hoffmann-La Roche

Merck

Pfizer

Roche

Novartis

Jiangsu HengRui Medicine

Innovent

Eli Lilly

GlaxoSmithKline

Market Ecosystem

The PD-1 and PD-L1 Antibody market ecosystem spans upstream raw material suppliers, midstream manufacturers, and downstream healthcare providers. Value is generated through collaborative R&D, clinical validation, and therapeutic application, with regulatory compliance and clinical evidence serving as critical gatekeepers. The ecosystem’s complexity reflects interdependencies across biotechnology innovation, manufacturing scalability, and patient access frameworks.

Raw material/component suppliers — supply monoclonal antibody precursors, conjugation agents, and bioreactor components

OEMs/Manufacturers — develop and produce PD-1/PD-L1 checkpoint inhibitors for oncology treatment

Technology providers — offer platform technologies for antibody engineering and biomarker identification

System integrators/EPCs — design combination therapies integrating immunotherapies with chemotherapy or targeted drugs

Distributors/Channel partners — manage commercialization, logistics, and reimbursement coordination

Healthcare providers — administer therapies, monitor patient outcomes, and report safety data

Regulators/standards bodies — enforce approval pathways, safety protocols, and post-market surveillance

Control points reside with regulators, who determine market entry through approval timelines, and technology providers, whose platform capabilities shape innovation speed. Dependency risks include raw material shortages, IP disputes, and evolving biomarker standards. Switching costs are high for manufacturers due to clinical validation requirements, while partnerships between integrators and distributors ensure interoperability across treatment ecosystems. Regional variations in reimbursement policies and clinical guidelines further segment ecosystem dynamics.

Recent Industry Insights

The PD-1 and PD-L1 Antibody industry trends have evolved rapidly over the past 18 months, driven by strategic collaborations, regulatory advancements, and innovation in immuno-oncology. Key developments include Merck & Co. expanding its Keytruda portfolio through a partnership with GSK to explore combination therapies for solid tumors, while Bristol-Myers Squibb strengthened its market position via the acquisition of CyrusInn Biosciences, enhancing its pipeline for novel immunotherapies. Product launches have focused on expanding indications, such as Pfizer’s BAVENCIO (avelumab) gaining approval for gastric cancer, and AstraZeneca’s Imfinzi securing new indications in bladder cancer. Regulatory bodies like the FDA have emphasized real-world evidence to support accelerated approvals, while the European Commission updated guidelines to streamline biomarker-driven trial designs. Meanwhile, funding surges in biotech startups—such as Adaptimmune Therapeutics raising $350M for T-cell therapy—signal investor confidence in next-gen immune-oncology platforms. As combination therapies and biosimilars gain traction, the industry is poised to shift toward personalized treatment paradigms and global market expansion.

Analyst Overview

The PD-1 and PD-L1 Antibody market remains highly attractive due to its transformative role in oncology, driven by rising cancer prevalence, improved patient outcomes, and expanding label approvals. The PD-1 and PD-L1 Antibody market outlook suggests sustained growth, underpinned by demand for immunotherapy combinations and niche indications. Competitive intensity is elevated, with key players dominating while emerging biotechs challenge through innovation. Long-term, the market is poised for expansion as regulatory pathways streamline and real-world evidence strengthens adoption.

Critical Insights3 items

Innovation landscape emphasizes next-gen antibodies, biomarker advancements, and bispecific formats to overcome resistance.

Demand-supply balance faces pressure from production complexities, but capacity investments are aligning with rising demand.

Key risk factors include pricing pressures, reimbursement challenges, and competitive biosimilar entrants post-patent expirations.

11 items

1. Executive Summary

2. PD-1 and PD-L1 Antibody Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global PD-1 and PD-L1 Antibody Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global PD-1 and PD-L1 Antibody Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Solid Tumors

6.1.2. Blood-related Tumors

6.2. Global PD-1 and PD-L1 Antibody Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. PD-1 inhibitor

6.2.2. PD-L1 inhibitor

6.3. Global PD-1 and PD-L1 Antibody Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global PD-1 and PD-L1 Antibody Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global PD-1 and PD-L1 Antibody Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global PD-1 and PD-L1 Antibody Market Competition by Key Manufacturers

8.1. Global PD-1 and PD-L1 Antibody Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global PD-1 and PD-L1 Antibody: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. AstraZeneca

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Bristol-Myers Squibb

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. F. Hoffmann-La Roche

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Merck

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Pfizer

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Roche

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Novartis

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Jiangsu HengRui Medicine

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Innovent

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Eli Lilly

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. GlaxoSmithKline

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global PD-1 and PD-L1 Antibody Market

Figure 4: Global PD-1 and PD-L1 Antibody Market: Drivers

Figure 5: Global PD-1 and PD-L1 Antibody Market: Challenges

Figure 6: Global PD-1 and PD-L1 Antibody Market: Trends

Figure 7: Global PD-1 and PD-L1 Antibody Market: Opportunity

Figure 8: Global PD-1 and PD-L1 Antibody Market: Restraint

Figure 9: Global PD-1 and PD-L1 Antibody Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global PD-1 and PD-L1 Antibody Market Value (USD Million) By Region

Figure 15: Global PD-1 and PD-L1 Antibody Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global PD-1 and PD-L1 Antibody Market Value (USD Million) By Region

Figure 23: Global PD-1 and PD-L1 Antibody Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

75 items

Table 1: Market Segmentation Analysis

Table 2: Global PD-1 and PD-L1 Antibody Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global PD-1 and PD-L1 Antibody Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global PD-1 and PD-L1 Antibody Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global PD-1 and PD-L1 Antibody Market Value (USD Million) By Region

Table 10: Global PD-1 and PD-L1 Antibody Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global PD-1 and PD-L1 Antibody Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global PD-1 and PD-L1 Antibody Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global PD-1 and PD-L1 Antibody Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: AstraZeneca Basic Information And Sales Area

Table 31: AstraZeneca. Products Portfolio

Table 32: Bristol-Myers Squibb Basic Information And Sales Area

Table 33: Bristol-Myers Squibb. Products Portfolio

Table 34: F. Hoffmann-La Roche Basic Information And Sales Area

Table 35: F. Hoffmann-La Roche. Products Portfolio

Table 36: Merck Basic Information And Sales Area

Table 37: Merck. Products Portfolio

Table 38: Pfizer Basic Information And Sales Area

Table 39: Pfizer. Products Portfolio

Table 40: Roche Basic Information And Sales Area

Table 41: Roche. Products Portfolio

Table 42: Novartis Basic Information And Sales Area

Table 43: Novartis. Products Portfolio

Table 44: Jiangsu HengRui Medicine Basic Information And Sales Area

Table 45: Jiangsu HengRui Medicine. Products Portfolio

Table 46: Innovent Basic Information And Sales Area

Table 47: Innovent. Products Portfolio

Table 48: Eli Lilly Basic Information And Sales Area

Table 49: Eli Lilly. Products Portfolio

Table 50: GlaxoSmithKline Basic Information And Sales Area

Table 51: GlaxoSmithKline. Products Portfolio

Table 52: Global Market Value (USD Million) (2025-2032) By Application

Table 53: Global Market Share (%) By Application (2032)

Table 54: Global Market Value (USD Million) (2025-2032) By Types

Table 55: Global Market Share (%) By Types (2032)

Table 56: Global PD-1 and PD-L1 Antibody Market Value (USD Million) By Region

Table 57: Global PD-1 and PD-L1 Antibody Market Share (%) By Region (2025-2032)

Table 58: North America Market Value (USD Million) (2025-2032) By Country

Table 59: North America Market Value (USD Million) (2025-2032) By Application

Table 60: North America Market Value (USD Million) (2025-2032) By Types

Table 61: Europe Market Value (USD Million) (2025-2032) By Country

Table 62: Europe Market Value (USD Million) (2025-2032) By Application

Table 63: Europe Market Value (USD Million) (2025-2032) By Types

Table 64: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 65: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 66: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 67: South America Market Value (USD Million) (2025-2032) By Country

Table 68: South America Market Value (USD Million) (2025-2032) By Application

Table 69: South America Market Value (USD Million) (2025-2032) By Types

Table 70: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 71: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 72: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 73: Research Programs/Design For This Report

Table 74: Key Data Information From Secondary Sources

Table 75: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

PD-1 and PD-L1 Antibody Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	18.50 billion
Revenue forecast in 2033	46.80 billion
Growth rate	CAGR of 12.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	AstraZeneca; Bristol-Myers Squibb; F. Hoffmann-La Roche; Merck; Pfizer; Roche; Novartis; Jiangsu HengRui Medicine; Innovent; Eli Lilly; GlaxoSmithKline
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options